CLINICAL PHARMACIST INTERVENTIONS ON MILIARY KOCH’S PATIENT WITH ANTITUBERCULAR THERAPY-INDUCED HEPATOTOXICITY AND PSYCHOSIS: A RARE CASE REPORT

Authors

  • ROHIT BANGWAL Department of Pharmacy Practice, Shree Dev Bhoomi Institute of Education Science and Technology, Dehradun, Uttarakhand, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i12.48098

Keywords:

Antitubercular drug therapy, Directly observed treatment short course, Psychosis, Miliary tuberculosis., KOCH’S

Abstract

Psychosis and hepatotoxicity are the dangerous side effects of the antitubercular drugs directly observed treatment short course (DOTS) therapy. Hematological spreading of tubercular bacteria in the lungs is also known as miliary tuberculosis. In this case study, 45-year-old man, weighing 55 kg was brought to the hospital with the chief complaints of vomiting (multiple episodes), fever, pain in abdomen, difficulty in breathing, mucoid cough, and disturbed sleep for the past 1 week. He had a known case of smear-positive pulmonary tuberculosis (in the past 1 month), but at that time, patient was not taking regular antitubercular treatment (ATT) medications (DOTS therapy). After 3th week of irregular antitubercular drug treatment, patient developed with the problems such as vomiting (multiple episodes), fever, pain in abdomen, difficulty in breathing, cough with expectorations, disturbed in sleep, and delirium. Pulmonologists had found the provisional and final diagnosis on the bases of subjective and objective observations miliary KOCH’S with antitubercular drugs induced hepatotoxicity and psychosis. Patients recovered from psychosis and hepatotoxicity withdrawn the first line ATT medication and tablet pyridoxine, antipsychotic medicines, and modified ATT were added in the therapy. Psychotic in a patient on ATT can be one of the complications of tablet isoniazid. As a clinical pharmacologist, we prevent and minimize drugs-induced complications and adverse drug reactions. Proper patients counseling and patients’ education are important for the better management of patients.

Downloads

Download data is not yet available.

References

Bangwal R, Joshi Y, Rawat S, Jangpani DS. Drug-induced hepatotoxicity of antitubercular drugs therapy: A case report. J Pharm Res 2019;8:266-8.

Bangwal R, Rawat J, Joshi Y. Hepatitis induced by anti-tubercular therapy and chronic alcoholism: A case report. J Drug Deliv Ther 2019;9:598-600.

Duggal HS, Nizamie SH. Novel antipsychotic drugs and INH-related psychosis. Aust N Z J Psychiatry 2000;34:343-4. doi: 10.1080/j.1440- 1614.2000.0719i.x, PMID 10789548

Baytunca MB, Erermis S, Bildik T, Kayahan B. Isoniazid-induced psychosis with obsessive-compulsive symptoms (schizo-obsessive disorder) in a female child. J Child Adolesc Psychopharmacol 2015;25:819-20. doi: 10.1089/cap.2014.0065, PMID 25265091

Witkowski AE, Manabat CG, Bourgeois JA. Isoniazid-associated psychosis. Gen Hosp Psychiatry 2007;29:85-6. doi: 10.1016/j. genhosppsych.2006.10.010, PMID 17189755

Bourgeois JA, Zelenko M, Waraich BS. Psychotic disorder associated with isoniazid. Mil Med 1996;161:707. doi: 10.1093/ milmed/161.11.707, PMID 8961730

Arya S, Sukhija G, Singh H. Acute psychosis after recent isoniazid initiation. J Clin Diagn Res 2015;9:VD01-2. doi: 10.7860/ JCDR/2015/12450.6130, PMID 26266198

Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol 2012;2:247-59. doi: 10.1016/j.jceh.2012.05.002, PMID 25755441

Schrestha S, Alao A. Isoniazid-induced psychosis. Psychosomatics 2009;50:640-1. doi: 10.1176/appi.psy.50.6.640-a, PMID 19996240

Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian pacific association for the study of the liver (APASL) 2014. Hepatol Int J 2014;8:453-71. doi: 10.1007/s12072-014-9580-2, PMID 26202751

Published

07-12-2023

How to Cite

BANGWAL, R. “CLINICAL PHARMACIST INTERVENTIONS ON MILIARY KOCH’S PATIENT WITH ANTITUBERCULAR THERAPY-INDUCED HEPATOTOXICITY AND PSYCHOSIS: A RARE CASE REPORT”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 12, Dec. 2023, pp. 1-3, doi:10.22159/ajpcr.2023.v16i12.48098.

Issue

Section

Case Study(s)